<DOC>
	<DOCNO>NCT00597246</DOCNO>
	<brief_summary>This research protocol make picture brain tumor . The picture make positron emission tomography ( PET ) scanner . PET scan use radioactivity `` see '' cancer cell . We use new kind PET scan . The new PET scan call [ 18F ] -FACBC PET . We compare standard PET scan . The standard PET scan call [ 11C ] -methionine PET . We expect picture give u information tumor . We also hope collect information amount radioactivity exposure . We measure radioactivity exposure tumor , brain organ . The research study result use support submission investigational new drug ( IND ) application Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>Imaging Brain Tumors With FACBC Methionine</brief_title>
	<detailed_description>The purpose research : 1 ) perform 3- [ 18F ] -FACBC [ 11C-methyl ] -Lmethionine brain tumor PET image study patient primary brain tumor previously treat suspect recurrence progression disease ( pilot study , n=20 ) ; 2 ) perform 3- [ 18F ] -FACBC PET image study additional set patient primary brain tumor previously treat suspect recurrence ( n=10 ) . 3 ) obtain organ/tissue body radiation dosimetry information follow i.v . injection 3- [ 18F ] -FACBC ; 4 ) look potential correlation scan result obtain patient enrolled 03-028 patient ' past medical treatment ; The first set 20 patient agree two PET study . One study involve i.v . administration fluorine-18 label amino acid analogue , 3-fluoro-aminocyclobutane carboxylic acid ( 3- [ 18F ] -FACBC ) sequential brain body PET imaging . The second study involve i.v . administration [ 11C-methyl ] -L-methionine head imaging . The additional set 10 patient undergo one PET study consist i.v . administration fluorine-18 label amino acid analogue , 3-fluoro-aminocyclobutane carboxylic acid ( 3- [ 18F ] -FACBC ) one brain scan one body scan . The 3- [ 18F ] -FACBC PET study ( n=30 ) perform Radioactive Drug Research Committee ( RDRC ) guideline define establish Federal Drug Administration ( FDA ) . [ 11C-methyl ] -L-methionine hospital formulary approve image brain tumor MSKCC . Our hypothesis include : 1 ) [ 18F ] -FACBC equal well brain tumor image characteristic compare [ 11C ] -methionine ; 2 ) [ 18F ] -FACBC metabolize , radiolabeled metabolite confound interpretation image case [ 11C ] -methionine ; 3 ) image recurrent brain tumor [ 18F ] -FACBC enhance low brain ( background ) activity compare correspond [ 11C ] - methionine image ; 4 ) biodistribution [ 18F ] -FACBC radiation dosimetry follow i.v . administration 370 MBq ( 10 mCi ) dose safe within FDA guideline ; 5 ) 370 MBq ( 10 mCi ) dose [ 18F ] -FACBC sufficient image brain tumor clinical setting ; 6 ) accumulation [ 18F ] -FACBC correlate patient response prior treatment provide prognostic information respect tumor progression survival .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Registered patient MSKCC . Childbearing age female must nonpregnant , nonlactating , must use adequate contraception surgically sterile . Karnofsky score 60 great . Children sit still 6090 minute , without sedation , include protocol . Patient tolerate lying still 90 minute session PET tomograph .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Brain</keyword>
	<keyword>CNS</keyword>
	<keyword>Central Nervous System</keyword>
</DOC>